Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase – Should You Buy?

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) saw unusually-strong trading volume on Tuesday . Approximately 2,510,131 shares changed hands during trading, an increase of 150% from the previous session’s volume of 1,002,875 shares.The stock last traded at $7.5480 and had previously closed at $6.58.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on FULC shares. Leerink Partners restated an “outperform” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Bank of America boosted their target price on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. initiated coverage on Fulcrum Therapeutics in a research report on Monday, January 12th. They set an “overweight” rating and a $20.00 target price on the stock. HC Wainwright increased their price target on Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, Truist Financial set a $17.00 price target on Fulcrum Therapeutics in a report on Tuesday, February 24th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Fulcrum Therapeutics Price Performance

The stock has a fifty day moving average of $9.01 and a 200 day moving average of $9.61. The stock has a market cap of $498.17 million, a price-to-earnings ratio of -6.34 and a beta of 3.23.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). As a group, equities analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FULC. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Fulcrum Therapeutics in the fourth quarter worth about $30,000. Quarry LP acquired a new position in Fulcrum Therapeutics in the third quarter valued at approximately $35,000. Meeder Asset Management Inc. purchased a new stake in Fulcrum Therapeutics in the 4th quarter worth approximately $39,000. Russell Investments Group Ltd. boosted its position in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock worth $65,000 after purchasing an additional 3,697 shares during the period. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.